Tesamorelin Long-Term Safety: 52-Week Extension Data, IGF-1 Monitoring, Antibodies and What Happens After Stopping

RESEARCH · TESAMORELIN · LONG-TERM SAFETY AND TOLERABILITY

Tesamorelin Long-Term Safety: 52-Week Extension Data, IGF-1 Monitoring, Antibodies and What Happens After Stopping

PurixLab’s Tesamorelin 5mg is a research vial of the stabilised GHRH(1-44) analogue. Our earlier articles cover a research overview, visceral fat and liver fat and glucose and HbA1c trials. This article asks a narrower question: what does the published record say about longer-term safety and tolerability? It covers the 26-week phase III trials and their 26-week extensions, the rise in IGF-1 and how regulators treat it, anti-drug antibodies, injection-site and hypersensitivity reactions, glucose as a safety signal, and what happened when treatment stopped. These are findings from clinical research under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

The trial programme behind the long-term data

Almost all long-term human data come from one development programme in people with HIV and excess abdominal fat. A 12-week placebo-controlled study in 61 patients came first and concluded that longer studies with more patients were needed to judge durability and safety [1]. Two phase III trials followed. In the first, 412 patients were randomised to tesamorelin or placebo for 26 weeks [2]. Both trials then used the same extension design: at week 26, people on tesamorelin were re-randomised either to continue or to switch to placebo for another 26 weeks, while those on placebo switched to tesamorelin [3,4]. A pooled analysis of both trials covered 806 patients, 543 on tesamorelin and 263 on placebo in the first phase; at week 26, 246 continued tesamorelin, 135 switched to placebo and 197 switched from placebo to tesamorelin [5]. This design is what allows the questions below to be asked at all, but it also sets their limit: the longest blinded exposure is 52 weeks.

What 52 weeks of exposure showed

In the first extension report, tesamorelin was generally well tolerated, and the prevalence of adverse events and serious adverse events in the extension was comparable with the initial phase. Visceral fat stayed about 18% below baseline over 52 weeks, and triglycerides stayed lower, while HDL cholesterol fell slightly [3]. In the pooled analysis, people who stayed on tesamorelin for the full year kept a visceral fat reduction of 17.5% from their original baseline, with lower waist circumference and triglycerides, and no clinically meaningful differences in glucose parameters at week 26 or 52 [5]. A 2011 review of the programme put treatment-emergent serious adverse events at under 4% of patients during 26 weeks, with most adverse events being injection-site reactions or effects known from growth hormone (GH) therapy, such as arthralgia, headache and peripheral oedema. The review also noted that longer-term clinical experience was still needed [6].

What happened after discontinuation

The re-randomisation at week 26 doubles as a withdrawal experiment. In the first trial’s extension, visceral fat reaccumulated after tesamorelin was stopped, and the authors concluded that the effect does not last beyond the duration of treatment [3]. The second trial reached the same conclusion more bluntly: the gains made over the first six months were rapidly lost in those who switched to placebo [4]. For researchers, this matters for study design. A trial endpoint measured on treatment says little about persistence, and any long-term model has to include a washout arm if durability is part of the question.

IGF-1 elevation and monitoring

Tesamorelin works by increasing the body’s own GH release, so IGF-1 rises by design. In the first phase III trial, IGF-1 rose by 81.0% on tesamorelin and fell by 5.0% on placebo [2]. The current US prescribing information gives the distribution: among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores (SDS) and 36% above 3 SDS, with the effect seen as early as week 13; at 52 weeks, 34% were above 2 SDS and 23% above 3 SDS. The label states that the effects of prolonged IGF-1 elevation are unknown, asks prescribers to monitor IGF-1, and suggests considering stopping in people with persistent elevations. It also carries warnings about neoplasms, fluid retention such as oedema, arthralgia and carpal tunnel syndrome, and possible worsening of diabetic retinopathy [7]. None of the published trials was long enough or large enough to settle the cancer question.

Anti-drug antibodies

Peptide analogues can provoke an immune response, and tesamorelin does. According to the label, anti-tesamorelin IgG antibodies were detected in 50% of patients after 26 weeks and 47% after 52 weeks, and in 85% of the subset who had hypersensitivity reactions. About 60% of antibody-positive patients showed cross-reactivity with the body’s own GHRH. Neutralising antibodies were detected in vitro at week 52 in 10% of patients against tesamorelin and 5% against human GHRH. In a group re-tested six months after stopping, 18% were still antibody positive. Patients with and without antibodies had similar reductions in visceral fat and similar IGF-1 responses, and the label cautions that antibody incidence depends heavily on the assay used [7]. The clinical meaning of cross-reactivity with native GHRH over longer periods has not been studied in published trials.

Injection-site and hypersensitivity reactions

Local reactions are the most consistent tolerability signal. The label reports injection-site reactions, such as erythema, pruritus, pain, irritation and bruising, in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks, and hypersensitivity reactions, including rash, urticaria and flushing, in 4% [7]. In the first phase III trial, overall adverse events did not differ significantly between groups, but more tesamorelin patients withdrew because of an adverse event [2]. A later 12-month liver-fat trial found more localised injection-site complaints with tesamorelin, none judged serious [8]. A 2026 meta-analysis of four randomised trials with 909 patients found GH-related adverse effects and a trend towards more discontinuations (risk ratio 2.25, 95% CI 0.98 to 5.17, p = 0.06) [9], and another meta-analysis listed arthralgia, myalgia, paraesthesia and injection-site erythema among associated adverse events [10].

Glucose as a safety signal

Because GH antagonises insulin, glucose was a pre-specified safety concern throughout. Average glucose measures did not change in a clinically meaningful way at 26 or 52 weeks in the phase III programme [3,5], and in the 12-month liver-fat trial, where glucose was the primary safety endpoint, fasting glucose and HbA1c did not differ between groups [8]. Averages can hide subgroups, however. The label reports HbA1c reaching 6.5% or more by week 26 in 5% of tesamorelin patients versus 1% on placebo, with an increased risk of developing diabetes relative to placebo [7]. An analysis of 402 patients initially assigned to tesamorelin split them by visceral fat response, defining responders as a reduction of at least 8%: non-responders had larger rises in fasting glucose and HbA1c than responders at both 26 and 52 weeks [11]. In a small analysis of people on integrase inhibitor-based therapy, adverse events, including hyperglycaemia, were similar between groups [12]. Our glucose article covers these data in more depth.

Limits of the evidence and open questions

  • One year is the ceiling. Blinded exposure ends at 52 weeks, and the meta-analyses describe long-term safety and durability data as limited [5,9].
  • One population. The safety database is dominated by people with HIV on antiretroviral therapy, so it may not generalise [2,5].
  • IGF-1 and malignancy. The consequences of sustained IGF-1 elevation are officially unknown [7].
  • Immunogenicity. Antibody rates are assay-dependent, and cross-reactivity with native GHRH has no long-term outcome data [7].
  • No lasting effect. Visceral fat returns after withdrawal, so any long-term study implies long-term exposure [3,4].
  • Different materials. All of the above concerns a regulated pharmaceutical product in supervised trials, not research-grade peptide material.

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-87. PubMed 16052083 · doi:10.1097/01.aids.0000180099.35146.30
  2. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
  3. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. PubMed 18690162 · doi:10.1097/QAD.0b013e32830a5058
  4. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PubMed 20101189 · doi:10.1097/QAI.0b013e3181cbdaff
  5. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
  6. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. PubMed 21668043 · doi:10.2165/11202240-000000000-00000
  7. Theratechnologies Inc. EGRIFTA SV (tesamorelin) prescribing information (revised 03/2024), section 5 Warnings and Precautions and section 12.6 Immunogenicity. U.S. National Library of Medicine DailyMed structured product label, set ID 3d783378-b02d-4f19-99dd-0fc91a042224. DailyMed SPL record
  8. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038 · PMC6981288 · doi:10.1016/S2352-3018(19)30338-8
  9. Ditta AM, Naeem RM, Sami MM, et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PubMed 42538058 · PMC13428105 · doi:10.1177/23259582261475549
  10. Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
  11. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-51. PubMed 22495074 · PMC3348954 · doi:10.1093/cid/cis251
  12. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PubMed 38905488 · PMC11365754 · doi:10.1097/QAD.0000000000003965

Leave a Comment

Your email address will not be published. Required fields are marked *